Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

November 10, 2017: By Jon Swedien

Second SightSecond Sight reported Nov. 2 that its Q3-2017 net sales totaled $1.6 million, compared with $1.2 million in the third quarter of 2016.

The Sylmar, California, developer of the Argus II retinal prosthesis said surgeons implanted 12 systems during the third quarter, compared with 19 in Q2-2017 and 14 in Q3-2016.

The Centers for Medicare and Medicaid Services (CMS) issued a final Medicare outpatient payment rate for 2018 of $122.5 thousand for the Argus II and the associated surgical implantation procedure, the company said. The 2017 reimbursement rate was $150 thousand, and the 2016 rate was $95 thousand.

Second Sight said it anticipates a strong Q4-2017, with more than 20 Argus II surgeries completed or scheduled as of Nov. 2.

For the first three quarters of 2017, Second Sight’s total revenues were $4.9 million compared with $3.3 million for the same period in 2016. This increase was mainly due to a higher number of implants and higher average revenues per implant in 2017 compared with the prior year, Second Sight said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022